About this trial
This randomized clinical trial aims to evaluate and compare the analgesic efficacy and functional outcomes of the quadro-iliac plane block (QIPB) and the pericapsular nerve group (PENG) block combined with lateral femoral cutaneous nerve(LFCN) block in patients undergoing total hip arthroplasty. The primary outcome is the Numeric Rating Scale (NRS) within the first 48 hours after surgery. Secondary outcomes include postoperative total opioid consumption, ıncidence of quadriceps motor block, time to first ambulation, block performance time, falls, length of hospital stay, block- related complications(hematoma,local anesthetic systemic complications, vascular puncture, and infection), patient satisfaction assessed using a Likert scale, and incidence of postoperative nausea and vomiting.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age between 18 and 80 years
American Society of Anesthesiologists physical status I-III
Scheduled for elective unilateral primary total hip arthroplasty
Surgery planned under spinal anesthesia
Disqualifiers
Refusal to participate
Revision total hip arthroplasty
Bilateral total hip arthroplasty
Contraindication to spinal anesthesia
Trial design
Parallel
Treatments tested in this trial
Quadro iliac Plane Block(QİPB)
Procedure/SurgeryParticipants allocated to the QIPB group will receive an ultrasound-guided quadro-iliac plane block after spinal anesthesia. Following standard aseptic preparation, 30 mL of 0.25% bupivacaine will be administered into the target fascial plane under ultrasound guidance after confirming the absence of blood on aspiration.
PENG Block and LFCN Blok
Procedure/SurgeryParticipants in the PENG group will undergo an ultrasound-guided pericapsular nerve group (PENG) block after spinal anesthesia. A total of 20 mL of 0.25% bupivacaine will be administered.
Lateral femoral cutaneous nerve block(LFCN)
Procedure/SurgeryParticipants in the LFCN group will undergo an ultrasound-guided lateral femoral cutaneous nerve block after spinal anesthesia. A total of 10 mL of 0.25% bupivacaine will be administered.
Treatment groups
Trial outcomes
Primary outcomes
Postoperative pain scores
Postoperative pain intensity will be assessed using an 11-point Numeric Rating Scale (NRS), where 0 indicates no pain and 10 indicates the worst imaginable pain. Pain scores at rest will be recorded in the post-anesthesia care unit and at postoperative 6, 24, 36, and 48 hours. Pain scores during movement will be assessed during passive flexion of the operated hip at postoperative 6, 24, 36, and 48 hours.
Secondary outcomes
Postoperative opioid consumption
Total postoperative opioid consumption will be recorded and cumulative opioid consumption will be calculated at postoperative 24 and 48 hours.
Incidence of quadriceps motor block
Quadriceps motor block will be assessed using knee extension testing and graded as: 0 = normal strength 1. = paresis 2. = paralysis. Motor block incidence will be defined as the presence of paresis or paralysis.
Time to first ambulation
Time from the end of surgery to the first successful ambulation.
Patient satisfaction
Patient satisfaction with postoperative analgesia will be assessed using a Likert scale.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: